Invion Ltd

ASX:IVX ISIN:AU000000IVX4

Invion Limited ASX:IVXInvion Ltd (ASX:IVX) (OTCMKTS:IVIXF) (FRA:7C8) is a life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan and Japan to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited.

 
 

News

Invion Limited (ASX:IVX) Prostate Cancer Trial Results

🕔9/18/2024 4:14:59 PM 2537

Invion Limited (ASX:IVX) wishes to announce that RMW Cho Group Limited (RMWC), the licensor of the Photosoft(TM) technology, has successfully completed a Phase II prostate cancer trial (ACTRN12621000633886) using a sublingual (under the tongue) formulation of INV043.

Read Full Article
###

690 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 16) (Last 30 Days: 91) (Since Published: 690) 

Company Data

    Headquarters
  • 100 Albert Road
    South Melbourne VIC 3205
    Australia
  • Telephone
  • +61 3 9692 7222 
  • Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Healthcare 
  • E:
  • investor@inviongroup.com

More News Results

  • 2024/12/03: Invion Doses First Patient in Phase I/II Skin Cancer Trial*
  • 2024/11/28: Completion of Securities Consolidation*
  • 2024/11/27: Notification regarding unquoted securities - IVX*
  • 2024/11/25: Section 708A Cleansing Statement*
  • 2024/11/25: Application for quotation of securities - IVX*
  • 2024/11/14: Results of Annual General Meeting*
  • 2024/11/14: AGM Presentation*
  • 2024/10/28: Change of Company Secretary*
  • 2024/10/28: Activities Report and Appendix 4C*
  • 2024/10/23: Section 708A Cleansing Statement*
*refer to company website